<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237779</url>
  </required_header>
  <id_info>
    <org_study_id>ATADEK 2019-4/23</org_study_id>
    <nct_id>NCT04237779</nct_id>
  </id_info>
  <brief_title>The Effects of Intratesticular PRP Injection in Men With Azoospermia or Cryptozoospermia</brief_title>
  <official_title>The Effects of Intratesticular PRP Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted in men with a diagnosis of non-obstructive azoospermia or&#xD;
      cryptozoospermia after obtaining written informed consent. The diagnosis of azoospermia and&#xD;
      cryptozoospermia will be based on two semen analyses performed at least 15 days apart,&#xD;
      followed by a documented micro testicular sperm extraction (TESE). A detailed history will be&#xD;
      obtained, physical examination and laboratory evaluation will be performed prior to&#xD;
      treatment. In physical examination, testicular volumes will be evaluated using an&#xD;
      orchiometer. Serum FSH and testosterone values will be determined. PRP will be prepared by&#xD;
      centrifugation of approximately 20 ml autologous blood obtained by phlebotomy. PRP (3 ml)&#xD;
      will be administered into the seminiferous tubule or interstitial space of each testis. Sperm&#xD;
      analysis, testicular volume (using orchiometer), serum FSH and testosterone levels will be&#xD;
      reevaluated at 8 weeks post-procedure. Micro TESE will performed on the third month after PRP&#xD;
      procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet-rich plasma (PRP) is a unique autologous agent derived from blood that is rich in&#xD;
      growth factors, cytokines, and hormones; it has been reported to reduce oxidative stress and&#xD;
      reactive oxygen species generation and upregulate the expression of various antioxidant&#xD;
      enzymes. PRP is used in a variety of clinical applications in cell therapy. Based on World&#xD;
      Health Organization guidelines, azoospermia is diagnosed when the absence of sperm is&#xD;
      observed in two semen samples. Based on World Health Organization (WHO), cryptozoospermia is&#xD;
      diagnosed when spermatozoa cannot be observed in a fresh semen sample; however, it is found&#xD;
      after an extended centrifugation and microscopic search. All patients require a clinical&#xD;
      work-up with physical examination, endocrine evaluation (follicle stimulating hormone (FSH),&#xD;
      luteinizing hormone (LH) and testosterone) and genetic analysis. Scrotal and transrectal&#xD;
      ultrasounds will be performed as indicated. Platelet-rich plasma (PRP), with its rich growth&#xD;
      factor composition, has proven beneficial in regenerative therapy. The potential therapeutic&#xD;
      role of PRP has not been studied in testis for non-obstructive azoospermia and&#xD;
      cryptozoospermia. The investigators will investigate sperm parameters in non-obstructive&#xD;
      azoospermic and crypotozoospermic patients treated with PRP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Actual">November 21, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sperm formation</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with testicular PRP treatment as assessed by testicular sperm extraction, change from azoospermia or cryptozoospermia to presence of sperm during TESE procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IVF outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with testicular PRP after TESE as assessed by number of clinical pregnancies, change in the clinical pregnancy rates with IVF treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Azoospermia, Nonobstructive</condition>
  <arm_group>
    <arm_group_label>PRP injection into at least one testis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in microTESE material.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP injection into at least one testis</intervention_name>
    <description>Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.</description>
    <arm_group_label>PRP injection into at least one testis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Azoospermia in at least 2 prior semen analysis.&#xD;
&#xD;
          -  Diagnosis of Non-Obstructive Azoospermia or Diagnosis of Cryptozoospermia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obstructive Azospermia&#xD;
&#xD;
          -  Anatomical abnormalities in the genital tract,&#xD;
&#xD;
          -  Cancer,&#xD;
&#xD;
          -  Hepatitis&#xD;
&#xD;
          -  Patients with systemic medical problems&#xD;
&#xD;
          -  Patients with chromosomal disorders&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Azoospermia in at least 2 prior semen analysis. Diagnosis of Non-Obstructive Azoospermia or Diagnosis of Cryptozoospermia</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yigit Cakiroglu, Assoc.Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Acibadem University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AcÄ±badem Maslak Hospital IVF Unit</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):189-97. doi: 10.4103/0974-2077.150734. Review.</citation>
    <PMID>25722595</PMID>
  </reference>
  <results_reference>
    <citation>Dehghani F, Sotoude N, Bordbar H, Panjeshahin MR, Karbalay-Doust S. The use of platelet-rich plasma (PRP) to improve structural impairment of rat testis induced by busulfan. Platelets. 2019;30(4):513-520. doi: 10.1080/09537104.2018.1478400. Epub 2018 Jun 8.</citation>
    <PMID>29883240</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>November 21, 2020</last_update_submitted>
  <last_update_submitted_qc>November 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Acibadem University</investigator_affiliation>
    <investigator_full_name>Bulent Tiras</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azoospermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

